1)Colorectal cancer patients who are scheduled to be on Regorafenib
2)Patients are scheduled to be administered the drugs at a dose of 120mg
4) Written informed consent for this study can be obtained from the patients.
1) Patients with fissure or erosion in the palmoplantar area
2) Patients with a history of sympathectomy
Incidence of hand-foot syndrome including all grades, duration until the initial presentation of hand-foot syndrome, duration until the presentaion of hand-foot syndrome with more than grade 2, duration between the presentation of hand-foot syndrome with more than grade 2 and the improvement in the symptoms with the grade decreased to grade 1 or 0, the incidence of cases with reducing the dose of Regorafenib due to hand-foot syndrome, incidence of drug withdrawal due to hand-foot syndrome, the incidence of cases with treatment withdrawal due to hand-foot syndrome, incidence of discontinue medication of regorafenib due to hand-foot syndrome, incidence of side effects by alminum chloride